KGLOW vs TB-500: What Is the Difference?
KGLOW contains TB-500 as one of four ingredients — and by molecule count it is the smallest contributor of the lot.
In plain English
KGLOW (or KLOW) is an 80 mg blend of GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg.
TB-500 on its own is a synthetic fragment of a protein found in almost every cell, studied for its role in cell movement and tissue organisation.
The difference, without the jargon
KGLOW contains 10 mg of TB-500 — the same amount as a standalone vial — but because TB-500 is the heaviest molecule in the mix, it accounts for only about 1% of the molecules present despite being 12.5% of the weight. GHK-Cu, being far smaller, dominates numerically. So if cell movement is the specific mechanism you care about, isolating TB-500 gives you a cleaner and more attributable result. Storage is also less demanding on its own: TB-500 needs darkness and minimal air, whereas KGLOW additionally needs neutral acidity and no chelating agents, both driven by its copper-containing majority ingredient.
Common questions
Does KGLOW contain TB-500?
Yes, 10 mg — the same as a typical standalone vial — alongside GHK-Cu, BPC-157 and KPV.
Why does TB-500 make up so little of the blend by molecule count?
Because it is by far the largest molecule present, at roughly 4963 units versus 340 for GHK-Cu. Weight and molecule count tell very different stories: 12.5% by weight works out to around 1% by molecule count.
Which is easier to store?
TB-500 alone. It needs protection from light and minimal air exposure. KGLOW needs those things plus neutral acidity and no chelating agents, because of the copper peptide that makes up most of it.
Technical reference below
How they actually differ
KGLOW contains 10 mg TB-500 alongside 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg KPV. Because TB-500 is the largest molecule in the mix at 4963 g/mol, it represents only about 1% of the preparation by molecule count despite being 12.5% by mass — worth knowing if actin-mediated cell migration is the mechanism you are actually studying. TB-500 alone also has a simpler handling profile: light protection for its methionine, and nothing else. KGLOW additionally requires neutral pH and freedom from chelators, both dictated by the GHK-Cu that makes up most of the vial.
KGLOW — origin
KGLOW is GLOW with a fourth component added: KPV, a tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. The other three amounts are unchanged — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg — with KPV at 10 mg bringing the vial to 80 mg. KPV is studied primarily for anti-inflammatory activity in preclinical models, notably retaining that property of the parent hormone without its pigmentation-related effects.
TB-500 (Thymosin Beta-4) — origin
TB-500 corresponds to the active region of Thymosin Beta-4, a 43-residue actin-sequestering protein present in virtually every mammalian cell type and abundant in wound fluid and platelets. Research interest followed the observation that the protein's activity in tissue-organisation models is largely retained by a short fragment of it.
KGLOW research themes
The majority component, with the deepest dermal research literature.
The addition that distinguishes KGLOW — studied for anti-inflammatory activity derived from alpha-MSH without pigmentation effects.
Two complementary tissue-repair mechanisms, unchanged from GLOW.
Adds an inflammation arm to the three repair-focused mechanisms in GLOW.
TB-500 (Thymosin Beta-4) research themes
The defining studied mechanism: binding G-actin and influencing the polymerisation equilibrium that governs cell motility.
Investigated in models where directed cell movement into a tissue defect is the measured endpoint.
Two of the better-populated preclinical literatures for the parent protein.
Studied for effects on inflammatory signalling in tissue-injury models.
KGLOW handling
- Never reconstitute in acidic diluent — copper dissociation from the GHK-Cu component is the primary risk.
- Keep EDTA and other chelators out of any buffer used with KGLOW.
- Treat colour as data: clear even blue is correct; pale or green is not.
- Protect from light and minimise headspace exposure for the TB-500 component.
- Scale diluent to the 80 mg fill — habitually adding 2 mL as though to a 10 mg vial gives a solution eight times more concentrated than intended.
TB-500 (Thymosin Beta-4) handling
- Minimise headspace exposure — each opening introduces oxygen that drives methionine oxidation.
- Keep reconstituted vials out of direct light, including bench lighting over long sessions.
- Introduce diluent against the vial wall; the cake is light and can be dispersed by a direct stream before it dissolves.
Both third-party tested
Every Popular Peptides batch of KGLOW and TB-500 (Thymosin Beta-4) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
KGLOW reference
Related comparisons
KGLOW and TB-500 (Thymosin Beta-4) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.